Icon

Time Sensitive

Ordering Recommendation

Use to detect and quantitate PML-RARA fusion transcripts in patients with acute promyelocytic leukemia. Use to monitor minimal residual disease and assess the risk of disease relapse.

Mnemonic

PML QNT

Methodology

Reverse Transcription Polymerase Chain Reaction

Performed

Varies

Reported

2-9 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Whole blood or bone marrow in lavender (EDTA).

Specimen Preparation

Whole Blood: Transport 5 mL whole blood. (Min: 3 mL)
Bone Marrow: Transport 3 mL bone marrow. (Min: 1 mL)
Refrigerate immediately. Specimens must be received within 48 hours of collection due to lability of RNA.

Storage/Transport Temperature

Whole Blood and Bone Marrow: CRITICAL REFRIGERATED. Separate specimens must be submitted when multiple tests are ordered.

Unacceptable Conditions

Serum, plasma, ambient or frozen bone marrow or whole blood, CSF, or FFPE tissue. Specimens collected   in anticoagulants other than EDTA. Severely hemolyzed or clotted specimens.
Ambient whole blood and ambient bone marrow specimens past 7 days will be cancelled. Refrigerated whole blood or bone marrow past 7 days will be canceled.

Remarks
Stability

Ambient: Unacceptable; Refrigerated: 48 hours; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81315

Components

Component Test Code* Component Chart Name LOINC
2002872 PML-RARA Translocation 21551-7
2002874 PML-RARA Translocation Quant 21785-1
3003498 PML-RARA Translocation Source 66746-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • AMPL' APL
  • APL MRD
  • APL Post-consolidation therapy testing
  • PML-RARA fusion types, A, B, B variant
  • PML-RARA long, short, variable types
  • PML-RARA S, L, V forms
  • PML_RARA fusion types
  • Quantitative PML
  • t(15;17)
PML-RARA Detection by RT-PCR, Quantitative (Test on Referral as of 1/17/2023)